Familial Mediterranean fever (FFI genetic disease) is an inherited autoinflammatory disorder that primarily affects populations of Mediterranean ancestry. The condition causes反复发作的炎症发作 that can damage organs over time if not properly managed.
Early diagnosis and consistent treatment reduce the risk of severe amyloidosis, a serious complication linked to FFI genetic disease. Understanding the genetic basis, symptoms, and available therapies helps people living with this condition maintain a better quality of life.
| Gene | Protein Produced | Main Function | Typical Mutation Effect |
|---|---|---|---|
| MEFV | Pyrin-Marenostrin | Regulates inflammation and immune response | Gain-of-function leads to excess interleukin-1 production |
| Inheritance Pattern | Autosomal Recessive | Requires two mutated copies for disease | Carrier with one mutation usually asymptomatic |
| Common Populations | Ashkenazi Jewish, Armenian, Arab, Turkish | Higher carrier rates in these groups | Carrier screening reduces incidence |
| Typical Onset Age | Childhood to early adulthood | Episodic attacks often begin before age 18 | Severity varies widely even within families |
Genetic Basis and Inheritance of FFI
MEFV Gene Mutations
Mutations in the MEFV gene disrupt pyrin-Marenostrin, a key inflammatory regulator. This disruption triggers excessive signaling through interleukin-1, leading to the hallmark inflammation episodes of FFI genetic disease.
Autosomal Recessive Pattern
Because FFI follows an autosomal recessive pattern, a person must inherit two faulty MEFV copies to develop the disease. Carriers with only one mutation generally do not show symptoms but can pass the variant to their children.
Symptoms and Attack Patterns
Acute Inflammatory Episodes
Attacks often involve fever, severe abdominal pain, chest pain, and inflamed joints. Some individuals also experience characteristic erysipelas-like skin lesions on the lower legs.
Long-Term Complications
Without consistent treatment, repeated inflammation can lead to amyloidosis, where abnormal protein deposits impair kidney function. Early intervention helps prevent or delay this serious complication of FFI genetic disease.
Diagnosis and Genetic Testing
Clinical Evaluation and Labs
Doctors rely on clinical history, exam findings, and elevated inflammatory markers during attacks to suspect FFI genetic disease. Genetic testing confirms pathogenic MEFV mutations and supports diagnosis.
Differential Diagnosis
Conditions such as appendicitis, Crohn disease, and certain autoimmune disorders can mimic FFI attacks. Comprehensive testing helps distinguish FFI from these look-alike illnesses.
Management and Long-Term Outlook
Daily Colchicine Therapy
Long-term colchicine reduces attack frequency, lowers inflammation, and dramatically decreases the risk of amyloidosis, making it the standard first-line treatment for FFI genetic disease.
Future Treatment Options
Emerging biologic agents targeting interleukin-1 or other inflammatory pathways provide additional options for patients who cannot tolerate or fully respond to colchicine.
- Confirm diagnosis with genetic testing and clinical evaluation
- Take colchicine daily as prescribed to prevent attacks and amyloidosis
- Seek immediate care for severe abdominal or chest pain
- Inform family members about carrier testing and reproductive options
- Maintain regular follow-up with a specialist experienced in FFI genetic disease
FAQ
Reader questions
Can two carrier parents have a child without FFI genetic disease?
Yes, each child has a 25% chance of being unaffected, a 50% chance of being a carrier, and a 25% chance of inheriting two mutations and having the disease.
Are there reliable prenatal tests for FFI genetic disease?
Prenatal genetic testing through chorionic villus sampling or amniocentesis can detect MEFV mutations if both parental mutations are known, allowing informed family planning decisions.
Do lifestyle changes alone control FFI genetic disease symptoms?
Lifestyle measures support overall health, but most individuals require regular anti-inflammatory medication, such as daily colchicine, to prevent attacks and amyloidosis.
How often do FFI attacks occur without treatment?
Without consistent therapy, attacks can range from monthly to several times per year, with variability influenced by age, environment, and other health factors.